Hepatocellular carcinoma is the most common primary liver cancer and is strongly associated with chronic liver disease and cirrhosis. Major risk factors include chronic hepatitis B or C infection, alcohol-related liver disease, and metabolic dysfunction-associated steatotic liver disease. Outcomes depend heavily on stage at diagnosis and liver function reserve.
New research links gut microbiome composition to cancer immunotherapy outcomes. A 674-patient study showed gut bacteria predict melanoma recurrence with up to 94% accuracy, while other studies identified specific microbes influencing treatment response and resistance in melanoma and liver cancer.
An armored GPC3-directed CAR T-cell therapy showed manageable safety and antitumor activity in refractory HCC, with 44.4% objective responses and 14.2-month median overall survival in a first-in-human trial.
AstraZeneca reported strong Q1 2026 results with 8% revenue growth and 12% operating profit growth, driven by its oncology portfolio and pipeline progress. The company also saw unusual options activity and maintained full-year guidance. Key oncology brands including Imfinzi and Enhertu showed double-digit growth.
Lidocaine patches cut opioid use after radiofrequency ablation for hepatocellular carcinoma; a protocol tests liposomal bupivacaine for mastectomy; a pipeline report profiles 40+ companies.
Studies highlight ferroptosis and cuproptosis in cancer therapy: a DDR1/VEGFR2 inhibitor reverses gastric cancer chemoresistance, GSH-responsive nanoparticles enhance HCC immunotherapy, and nutrient restriction boosts Sorafenib-induced ferroptosis.
New research links coffee to lower liver disease risk and sugary beverages to higher liver cancer risk. Two studies appear in Clinical Gastroenterology and Hepatology and JAMA Network Open.
Can-Fite will present late-stage pipeline at BIO 2026; GlobalData counts over 2,000 peptides in development with $91.38bn 2025 sales; Arrowhead's RNAi pipeline has two Phase 3 programs.
The FDA has cleared CStone Pharmaceuticals' investigational new drug application to begin a Phase II trial of its trispecific antibody CS2009 in advanced solid tumors. The multicenter trial will evaluate monotherapy and combination regimens across nine cancer types in Australia, China, and the U.S. Initial Phase I data showed a favorable safety profile and encouraging antitumor activity.
AI-driven studies are advancing cancer drug discovery across multiple tumor types, including a pan-cancer proposal of AMG-900, a novel gp130 inhibitor for colorectal cancer, and the Kinic Index for hepatocellular carcinoma. Machine learning is also being integrated into computational platforms like Isomorphic Labs' IsoDDE to model molecular interactions.
The FDA has approved Pfizer's BRAFTOVI for BRAF V600E metastatic colorectal cancer and VEPPANU for ESR1 mutated breast cancer. The oncolytic virus cancer therapy pipeline expands with over 120 companies developing 125+ drugs. Positive late-stage data for other Pfizer oncology programs was also reported.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07764835 |
Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC) |
NOT_YET_RECRUITING | |
| NCT07760012 |
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors |
RECRUITING | NA |
| NCT07732686 |
Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry |
NOT_YET_RECRUITING | |
| NCT07704203 |
Preoperative 3D Magnetic Resonance Elastography for Predicting Surgical Risk in Patients Undergoing Hepatectomy |
NOT_YET_RECRUITING | |
| NCT07691762 |
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma |
NOT_YET_RECRUITING | PHASE3 |
| NCT07690683 |
Patients With Hepatocellular Carcinoma (HCC) |
NOT_YET_RECRUITING | NA |
| NCT07685548 |
AI-Driven Tumor Response Evaluation for Solid Tumors |
NOT_YET_RECRUITING | |
| NCT07664007 |
Effects of EPA Supplementation on Patients With Unresectable Hepatocellular Carcinoma. |
COMPLETED | NA |
| NCT07658586 |
AI Multimodal Model for Liver Cancer Diagnosis and Prognosis |
ACTIVE_NOT_RECRUITING | |
| NCT07657273 |
Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
